Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Cash & Equivalents (2016 - 2025)

IGC Pharma (IGC) has disclosed Cash & Equivalents for 16 consecutive years, with $1.1 million as the latest value for Q3 2025.

  • Quarterly Cash & Equivalents fell 28.53% to $1.1 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Sep 2025, down 28.53% year-over-year, with the annual reading at $405000.0 for FY2025, 66.19% down from the prior year.
  • Cash & Equivalents for Q3 2025 was $1.1 million at IGC Pharma, up from $454000.0 in the prior quarter.
  • The five-year high for Cash & Equivalents was $14.5 million in Q1 2021, with the low at $405000.0 in Q1 2025.
  • Average Cash & Equivalents over 5 years is $5.3 million, with a median of $3.0 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents surged 1151.0% in 2021, then crashed 78.6% in 2023.
  • Over 5 years, Cash & Equivalents stood at $11.9 million in 2021, then tumbled by 58.59% to $4.9 million in 2022, then plummeted by 72.13% to $1.4 million in 2023, then plummeted by 65.89% to $470000.0 in 2024, then soared by 135.11% to $1.1 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $1.1 million, $454000.0, and $405000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.